Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors.

The focus of the company’s presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28.

The company’s stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%.

While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds

Disclosure: None.